Chargement en cours...
EGFR-Targeted Therapies in the Post-Genomic Era
Over ninety percent of head and neck cancers overexpress the epidermal growth factor receptor (EGFR). In diverse tumor types, EGFR overexpression has been associated with poorer prognosis and outcomes. Therapies targeting EGFR include monoclonal antibodies, tyrosine kinase inhibitors, phosphatidylin...
Enregistré dans:
| Publié dans: | Cancer Metastasis Rev |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5693744/ https://ncbi.nlm.nih.gov/pubmed/28866730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10555-017-9687-8 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|